Neither medication is universally safer for every patient
Graphical abstract Similar content being viewed by others Introduction Tirzepatide (LY3298176) is the first peptide dual agonist for type 2 diabetes mellitus (T2DM), which targets both GIPR and GLP1R
The powder should dissolve completely within one to five minutes
Though the medication was originally developed as a diabetes drug, its been shown to be effective for a myriad of conditions, like polycystic ovarian syndrome and migraines
Conversely, low-dose GLP-1 therapy is not appropriate for patients without established indications, particularly those seeking anti-inflammatory effects alone without diabetes or obesity
Among those not currently using GLP-1 medications, 4% of respondents said they have concrete plans to begin using GLP-1 in the next 12 months, while an additional 13% said they are considering starting the medication